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Martinez-Moreno et al. report a role for a
long non-coding RNA antisense to the
promoter of Egr2, Egr2-AS-RNA, during
the response to peripheral nerve injury.
Inhibition of Egr2-AS-RNA following
sciatic nerve injury reverts EGR2-
mediated gene expression and delays
demyelination.
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Precise regulation of Egr2 transcription is fundamen-
tally important to the control of peripheral myelina-
tion. Here, we describe a long non-coding RNA anti-
sense to the promoter of Egr2 (Egr2-AS-RNA). During
peripheral nerve injury, the expression of Egr2-AS-
RNA is increased and correlates with decreased
Egr2 transcript and protein levels. Ectopic expres-
sion of Egr2-AS-RNA in dorsal root ganglion (DRG)
cultures inhibits the expression of Egr2 mRNA and
induces demyelination. In vivo inhibition of Egr2-
AS-RNA using oligonucleotide GapMers released
from a biodegradable hydrogel following sciatic
nerve injury reverts the EGR2-mediated gene expres-
sion profile and significantly delays demyelination.
Egr2-AS-RNA gradually recruits H3K27ME3, AGO1,
AGO2, and EZH2 on the Egr2 promoter following
sciatic nerve injury. Furthermore, expression of
Egr2-AS-RNA is regulated through ERK1/2 signaling
to YY1, while loss of Ser184 of YY1 regulates binding
to Egr2-AS-RNA. In conclusion, we describe func-
tional exploration of an antisense long non-coding
RNA in peripheral nervous system (PNS) biology.
INTRODUCTION
In the vertebrate peripheral nervous system (PNS), Schwann
cells (SCs) produce the myelin sheath, the specialized mem-
brane structure that allows rapid nerve conduction. In recent
years, significant progress has been made in the identification
of key transcriptional regulators of myelination. Evidence gener-
ated in the mouse suggests that the transcription factor EGR2
plays the role of a central regulator in this process: (1) EGR2 is
activated in SCs after axonal contact, before myelination (Mur-
phy et al., 1996; Topilko et al., 1994); (2) Egr2 null or hypomorphic
mutations result in blockade of SCs at the promyelinating stage,
after the establishment of a 1:1 ratio with the axons, rendering1950 Cell Reports 20, 1950–1963, August 22, 2017 ª 2017 The Autho
This is an open access article under the CC BY-NC-ND license (http://them unable to proceed with the myelination process (Le et al.,
2005; Topilko et al., 1994); (3) forced Egr2 expression in SCs re-
sults in the activation of genes encoding structural myelin pro-
teins and enzymes involved in lipid synthesis (Nagarajan et al.,
2001); and (4) downregulation of EGR2 expression after periph-
eral nerve injury results in demyelination (Ghislain et al., 2002;
Zorick et al., 1996). In addition to mouse studies, the association
of various dominant or recessive Egr2 mutations with several
types of human peripheral neuropathies supports the crucial
role of Egr2 in the control of SC myelination (Bellone et al.,
1999; Timmerman et al., 1999; Warner et al., 1998).
Intracellular signaling pathways activated by both membrane-
bound and soluble neuregulins regulate the expression of EGR2
in SCs (Murphy et al., 1996; Svaren and Meijer, 2008; Taveggia
et al., 2005). Activation of theMEK-ERK1/2 cascade by neuregu-
lin is responsible for activation of the YY1 transcription factor,
which binds to the Egr2 promoter and regulates Egr2 expression
(He et al., 2010). Ablation of ERK/12 signaling in Erk1/2CKO(Dhh)
sciatic nerves leads to profound inhibition of EGR2 expression
and severe hypomyelination (Newbern et al., 2011).
The aforementioned studies reflect the ‘‘classical’’ paradigm
of transcriptional regulation, where signaling intermediates acti-
vate transcription factors, which in turn bind specific DNAmotifs
located on promoters to regulate the expression of target genes.
However, the role of epigenetic mechanisms (here taken tomean
mechanisms such as histone modifications and non-coding
RNAs (ncRNAs) that alter gene expression without changing
the DNA sequence) orchestrated by ncRNAs that regulate tran-
scription (Hawkins and Morris, 2008) have not been studied. In
human cells, there are two independent mechanisms that confer
transcriptional gene silencing (TGS): (1) a microRNA (miRNA)-
directed mechanism and (2) a long-antisense RNA mechanism
(Morris, 2009). Both short-(miRNA)- and long-(antisense)-RNA-
mediated TGS in human cells involves the interaction of RNA
with promoter regions (Kim et al., 2008; Klase et al., 2007; Omoto
and Fujii, 2005; Tan et al., 2009).
Here, we describe a long ncRNA (lncRNA) antisense to the
proximal promoter of Egr2. Egr2-AS-RNA shows increased
expression during acute peripheral nerve injury. Expression of
Egr2-AS-RNA regulates the levels of Egr2 in SCs, and in vivors.
creativecommons.org/licenses/by-nc-nd/4.0/).
inhibition of Egr2-AS-RNA results in rescue of the EGR2-
mediated gene expression profile and delay of demyelination
following peripheral nerve injury. Egr2-AS-RNA gradually re-
cruits an epigenetic remodeling complex on the Egr2 promoter,
while expression of Egr2-AS-RNA is regulated by ERK1/2
signaling to YY1, which binds to Egr2-AS-RNA in the context
of chromatin. Finally, YY1 mediates the interaction between
Egr2-AS-RNA and the chromatin remodeling factor ESH2,
while loss of Ser184 of YY1 induces direct binding of YY1 to
Egr2-AS-RNA.
RESULTS
Discovery of an Antisense lncRNA at the 50 UTR of Egr2
We have recently shown that miR-709 induces TGS of Egr2 by
binding to the myelin-specific element (MSE) region of the Egr2
promoter (Adilakshmi et al., 2012). These data generated a hy-
pothesis regarding the possible transcriptional regulation of the
proximal promoter of Egr2 by antisense RNA. To determine
whether an antisense lncRNA is present at the 50 UTR of Egr2,
we employed a modified rapid amplification of cDNA ends
(50-RACE) protocol to amplify the antisense strand. The resulting
antisense product was cloned, and the sequence is presented in
Figure S1A. Attempts to extend the RACE amplification further
upstream using primer walking did not reveal any results (data
not shown), which suggests that either the antisense RNA is
1,000 nt long or that it is partially amplified with our RACE
protocol. Next, we performed a homology search using the rat
antisense sequence against the mouse genome to identify the
degree of homology between rat and mouse. This search
showed 92%homology (Figure S1B), which allowed us to design
mouse-specific primers and perform strand-specific RT-PCR to
amplify the antisense product from total RNA isolated from
mouse sciatic nerves. To determine whether this AS-RNA had
been identified before, we performed a BLAST search using
LNCipedia (Volders et al., 2013, 2015) and lncRNAdb (Amaral
et al., 2011; Quek et al., 2015). The search returned no matches,
which suggests that this RNA is a previously undescribed
long non-coding antisense RNA that we subsequently refer to
as Egr2-AS-RNA. Finally, to independently validate the expres-
sion of Egr2-AS-RNA, we examined publicly available RNA-
sequencing (RNA-seq) data from three mouse sciatic nerves to
identify RNA-seq reads that map to the identified AS-RNA tran-
script (Poitelon et al., 2016). We found that the number of reads
per kilobase per million (RPKM) of Egr2-AS-RNA ranges be-
tween 1.6 and 2.5 and is on average 5 times more than the me-
dian number of RPKM over the entire 26,000 RefSeq tran-
scripts (Table S1A) in sciatic nerves. In addition, the average
relative abundance of Egr2-AS-RNA in the three sciatic nerves
was 43 times lower than the expression levels of the Egr2 tran-
script (Table S1B). Then, we estimated the coordinates ofmature
Egr2-AS-RNA and identified that the mature Egr2-AS-RNA
sequence spans a 470-nt region (chromosome 10 [chr10],
67537250–67537720) with almost perfect sequence fidelity (Fig-
ures S2A and S2B). The discrepancy between the length of
mature AS-RNA (470 nt) and the sequence detected by the
RACE protocol (1,000 nt) can be attributed to the random dec-
amers used for the amplification of the RACE product and thepossibility that part of Egr2-AS-RNA could be spliced after 50
end capping.
Egr2-AS-RNA Is Expressed in Mouse Sciatic Nerves and
Is Significantly Increased following Nerve Injury
To determine whether Egr2-AS-RNA is expressed during post-
natal development of the mouse sciatic nerve, we performed
strand-specific qPCR using RNA isolated from postnatal day 1
(P1), P5, P7, and 3-month-old mouse sciatic nerves. This
showed that Egr2-AS-RNA is expressed throughout these time
intervals, with the highest expression in P1 sciatic nerves (Fig-
ure 1A). To detect the expression and cell specificity of Egr2-
AS-RNA in mouse sciatic nerves, we performed multiplex
fluorescence in situ hybridization targeting Egr2-AS-RNA in
combination with mouse S100b, which was used as an SC-
specific marker. We detected a signal specific for Egr2-AS-
RNA in the cytoplasm (Figure 1B, arrowheads) and the nucleus
(Figure 1B, arrow) of S100b-positive SCs.
To examine whether Egr2-AS-RNA plays a role in the regula-
tion of Egr2 expression after peripheral nerve injury, we per-
formed strand-specific qPCR to detect the expression of Egr2-
AS-RNA and Egr2 mRNA 6 hr, 12 hr, 24 hr, 2 days, 5 days, and
7 days followingmouse sciatic nerve transection. We discovered
that the expression of Egr2-AS-RNA exhibits a statistically signif-
icant increase 6 and 12 hr after sciatic nerve injury (Figure 1C).
The expression of Egr2 mRNA shows statistically significant
downregulation at 12 and 24 hr (Figure 1D) and rebounds at
days 2, 5, and 7, when expression of Egr2-AS-RNA is minimal.
Finally, EGR2 protein expression in sciatic nerve lysates is signif-
icantly reduced by 48 hr after injury (Figures S3A and S3B).
Quantification of Absolute Levels of Egr2-AS-RNA in
Mouse Sciatic Nerves
In order to determine the absolute abundance of Egr2-AS-RNA
in mouse sciatic nerves, we prepared limiting dilutions (10 ng
to 1 pg) of a known amount of Egr2-AS-RNA and generated a
standard amplification curve of the dilutions using qPCR as
described before (Lu and Tsourkas, 2009). The Ct values ob-
tained from the amplification of Egr2-AS-RNA were then pro-
jected on the standard curve to determine the concentration of
Egr2-AS-RNA per 100 ng total RNA, which was used as template
in all qPCR reactions. This analysis showed that the average
concentration of Egr2-AS-RNA in non-injured sciatic nerves
was 200 pg/100 ng RNA, while, in injured nerves, the average
concentration fluctuated between 350 and 650 pg/100 ng
RNA, depending on the time interval following nerve injury (Fig-
ure 1E). The low expression levels of Egr2-AS-RNA are within
the range of expression of lncRNAs in eukaryotic cells (Mortazavi
et al., 2008; Palazzo and Lee, 2015; Ramsko¨ld et al., 2009). The
fact that expression levels increase by an average of 4-fold
following sciatic nerve injury implies specific functionality of
Egr2-AS-RNA in injured peripheral nerves.
Ectopic Expression of Egr2-AS-RNA Results in
Demyelination and Inhibition of Egr2 mRNA Expression
Since increased Egr2-AS-RNA expression correlates with
reduced Egr2 mRNA levels after sciatic nerve injury, we sought
to demonstrate that Egr2-AS-RNA could induce silencing ofCell Reports 20, 1950–1963, August 22, 2017 1951
Figure 1. AnEgr2Antisense RNA Transcript Is Expressed during Sciatic Nerve Development and Is Upregulated after Peripheral Nerve Injury
(A) Expression of Egr2-AS-RNA was detected by strand-specific qPCR in P1, P5, P7, and 3-month-old mouse sciatic nerves.
(B) In situ hybridization inmouse sciatic nerves shows the expression of Egr2-AS-RNA (green signal) in the cytoplasm (arrowheads) and nucleus (arrow) of S100b-
positive (red signal) SCs. Positive control shows expression of cyclophilin B (PPIB) (green) and POLR2A (RNA polymerase II polypeptide) (red). Negative control
shows no signal using a bacterial dapB probe. Scale bar, 100 mm.
(C) Expression of Egr2-AS-RNA in non-injured sciatic nerves and in sciatic nerves 6 hr, 12 hr, 24 hr, 2 days, 5 days, and 7 days following sciatic nerve injury. The
experiments were repeated three times, and significance was calculated with a one-way ANOVA (F (6,22) = 22.19, p < 0.0001) followed by a post hoc Dunnett’s
test (**p < 0.005, ****p < 0.00005).
(D) Expression of Egr2 mRNA in non-injured sciatic nerves and in sciatic nerves 6 hr, 12 hr, 24 hr, 2 days, 5 days, and 7 days following sciatic nerve injury. The
experiments were repeated three times, and the results are presented as mean ± SD. Significance was calculated with a one-way ANOVA (F (6,15) = 9.458,
p < 0.0001) followed by a post hoc Dunnett’s test (***p < 0.0005).
(E) Absolute abundance of Egr2-AS-RNA is significantly lower in control sciatic nerves than in injured nerves as determined by a one-way ANOVA (F = 6.935,
p = 0.0161) using sciatic nerves from 3 mice per condition.Egr2 transcript expression. We generated a lentivirus expressing
Egr2-AS-RNA to infect mouse dorsal root ganglion (DRG)
explant cultures 14 days after the addition of ascorbic acid to
ensure the presence of myelinated axons. We demonstrate
that overexpression of Egr2-AS-RNA (Figure 2E) results in sta-
tistically significant inhibition of Egr2 mRNA expression as
detected by qPCR (Figure 2A). In addition, ectopic expression
of Egr2-AS-RNA results in statistically significant inhibition of
EGR2 protein expression (Figure 2B). To examine the effect of
the ectopic expression of Egr2-AS-RNA on myelination, we in-
fected myelinated mouse DRG cultures with pLenti-AS-RNA or
pLenti-control. To show the specificity of the effect of Egr2-
AS-RNA on myelination, we incubated the pLenti-AS-RNA-
infected cultures with a scrambled oligonucleotide GapMer
(scrambled complementary strand of the AS-RNA) or an
Egr2-AS-RNA GapMer (complementary to the Egr2-AS-RNA
sequence). One week after infection and treatment with the
GapMers, we stained the cultures with myelin basic protein1952 Cell Reports 20, 1950–1963, August 22, 2017(MBP) and neurofilament (NF) antibodies to detect myelin inter-
nodes and integrity of the underlying axons, respectively (Fig-
ure 2C). Infection with the pLenti-AS-RNA induces significant
expression of Egr2-AS-RNA, which is not affected by the addi-
tion of scrambled GapMers, while Egr2-AS-RNA GapMers
induce a significant reduction in the amount of Egr2-AS-RNA in
the cultures (Figure 2E). Moreover, addition of Egr2-AS-RNA
GapMers rescues the demyelination phenotype observed in cul-
tures infected with pLenti-AS-RNA, while scrambled GapMers
have no effect (Figures 2D and 2F). There was no difference in
total cell numbers between the cultures (Figure S3C).
Inhibition of Egr2-AS-RNA Expression Using
Oligonucleotide GapMers Results in Delay of
Demyelination following Peripheral Nerve Injury
We developed an in situ, non-swelling, biodegradable hydrogel
(O’Shea et al., 2015) loaded with oligonucleotide GapMers
(20-mers) against Egr2-AS-RNA. The GapMer-infused hydrogel
Figure 2. Ectopic Expression of Egr2-AS-RNA Inhibits the Expression of Egr2 mRNA and Induces Demyelination
(A) Lenti-AS-RNA-infected cultures exhibit a significant decrease in the expression of the Egr2 mRNA as compared to Lenti-control infected cultures. The
experiment was repeated three times, and significance was calculated with a two-tailed unpaired Student’s t test (**p = 0.0005, t = 5.571, df = 8). Results are
presented as mean ± SD.
(B) Representative western blot showing expression of EGR2 after infection of DRG cultures with Lenti-control or Lenti-AS-RNA. Actin was used as loading
control. Densitometric analysis shows that ectopic expression of Egr2-AS-RNA results in a statistically significant decrease in EGR2. The results are presented as
mean ± SD from n = 5 per condition. Significance was calculated with a two-tailed unpaired Student’s t test (t = 4.722, df = 8, *p = 0.015).
(C) Representative images of Lenti-control- and Lenti-AS-RNA-infected DRG cultures showing extensive demyelination in the cultures infected with Lenti-AS-
RNA. Myelinated internodes were stained with MBP (red), and nuclei were stained with DAPI (blue) (top). The lower left panel shows a higher magnification of the
myelin internodes (stained red with MBP) and axons (stained green with neurofilament) in Lenti-control-infected cultures. In Lenti-AS-RNA-infected cultures, we
detected myelin debris (stained red with MBP), while the axons retain their integrity expressing NF (green). Scale bars, 100 mm.
(D) Rescue of AS-RNA induced demyelination with oligonucleotide inhibitors of Egr2-AS-RNA (GapMers).
(E) Lenti-AS-RNA-infected cultures exhibit significant increase in the expression of AS-RNA as compared to Lenti-control infected cultures, and the expression of
AS-RNA is not affected by the addition of scrambled GapMers (two-tailed, unpaired Student’s t test, p = 0.0135, t = 3.458, df = 6). Treatment of Lenti-AS-RNA-
infected DRG cultures with Egr2-AS-RNA-specific GapMers results in significant inhibition of Egr2-AS-RNA expression as compared to Lenti-AS-RNA-infected
cultures treated with scrambled GapMers (two-tailed, unpaired Student’s t test, p = 0.0001, t = 14.04, df = 6).
(F) Myelin internodes from ten 103 fields per culture from 4 cultures per condition were measured, and the results are presented as mean ± SD. Significance was
calculated with a two-tailed unpaired Student’s t test. Lenti-AS-RNA-infected cultures treated with a control (scrambled) GapMer have significantly fewer
myelinated internodes than Lenti-control-infected cultures (p = 0.0007, t = 5.352, df = 8). An Egr2-AS-RNA-specific GapMer rescues the Lenti-AS-RNA-infected
cultures from AS-RNA-induced demyelination (p < 0.0001, t = 7.949, df = 70).was applied to the sciatic nerve at the time of transection.We de-
signed five GapMers targeting different areas of the Egr2-AS-
RNA and a scrambled GapMer for control. Four GapMers
induced significant inhibition of Egr2-AS-RNA expression as
compared to transected nerves that received hydrogel only or
hydrogel plus scrambled GapMers (Figure 3A). Inhibition of
Egr2-AS-RNA expression with each of these GapMers results
in statistically significant increase in the expression of Egr2
mRNA following peripheral nerve injury (Figure 3B). Using elec-
tron microscopy, we discovered that addition of the hydrogel
plus GapMer at the time of sciatic nerve transection delays theinjury-induced demyelination at days 2, 5, and 7 after nerve injury
compared to injured nerves alone or injured nerves treated
with hydrogel plus scrambledGapMer (Figure 3C). Subtherapeu-
tic concentrations of GapMer remained within the hydrogel
beyond 7 days, consistent with in vitro release results for bio-
macromolecules of a similar molecular weight (O’Shea et al.,
2015), and consequently, the study was not extended further.
Inhibition of Egr2-AS-RNA expression using GapMers results
in a significant reduction in the percentage of demyelinated
fibers and an increase in the percentage of myelinated fibers
2, 5, and 7 days following complete sciatic nerve transectionCell Reports 20, 1950–1963, August 22, 2017 1953
Figure 3. In Vivo Inhibition of Egr2-AS-RNA Expression Results in Delayed Demyelination after Sciatic Nerve Injury
(A) Effect of five separate oligonucleotide GapMers complementary to five different sequence motifs of Egr2-AS-RNA on the expression of Egr2-AS-RNA in
mouse sciatic nerves. Quantification was performed with qPCR, combining RNA from 3 separate mice per individual GapMer. Four GapMers induced significant
inhibition of AS-RNA expression (one-way ANOVA [(5,13) = 5.846, p = 0.0111] followed by a post hoc Dunnett’s test [*p < 0.05]) as compared to transected nerves
that received hydrogel only (lesion) or hydrogel plus scrambled GapMers.
(B) Inhibition of AS-RNA with each of these GapMers results in significant increase in the expression of Egr2 mRNA as compared to non-treated or
scrambled-GapMer-treated injured sciatic nerves (one-way ANOVA [F(5,7) = 7.175, p = 0.0111] followed by post hoc Dunnett test [*p < 0.05], 3 sciatic nerves per
condition).
(C) Nerves that received hydrogel only or hydrogel plus scrambled GapMers show varying degrees of demyelination and axonal damage at 2, 5, and 7 days after
sciatic nerve transection. Animals treated with hydrogel plus GapMer appear to have less demyelination and axonal degeneration, and the endoneural space
appears more compact without extensive collagen depositions, which is more evident at day 7 as compared to animals treated with hydrogel only or hydrogel
plus scrambled GapMers.
(D) Quantification of the myelinated and demyelinated fibers as a percentage of the total number of fibers in non-treated, hydrogel-plus-scrambled-GapMer-
treated, and hydrogel-plus-GapMer-treated nerves following sciatic nerve injury. Inhibition of Egr2-AS-RNA expression using specific oligonucleotide GapMers
results in significant reduction in the percentage of demyelinated fibers and an increase in the percentage of myelinated fibers 2, 5, and 7 days following complete
sciatic nerve transection (*p < 0.05, two-tailed Student’s t test of unpaired samples).
(legend continued on next page)
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(Figure 3D). A statistically significant increase in the total number
of myelinated fibers 5 and 7 days following complete sciatic
nerve transection was also observed (Figure 3E).
In Vivo Inhibition of Egr2-AS-RNA Expression Rescues
the EGR2-Mediated Gene Expression Profile following
Peripheral Nerve Injury
As shown above (Figure 1C), peripheral nerve injury results in an
acute and significant increase in Egr2-AS-RNA expression up to
12 hr post-injury. To determine how Egr2-AS-RNA affects the
expression of EGR2-regulated transcripts following sciatic nerve
injury, we treated sciatic nerves with hydrogel plus GapMer to
inhibit the expression of Egr2-AS-RNA at the time of sciatic nerve
transection and up to 5 days post-injury. This showed that inhi-
bition of Egr2-AS-RNA expression in fully transected nerves res-
cues the inhibition of Egr2 transcript expression (Figure 4A) and
either rescues or delays the inhibition of EGR2-regulated genes
that encode structural myelin proteins or transcription factors
(Figure 4A). To determine whether the delayed inhibition of
gene expression results in delayed downregulation of PMP22
and MPZ myelin protein expression, we analyzed sciatic nerve
lysates treated with hydrogel plus GapMer or hydrogel plus
scrambled GapMer and untreated injured nerves 2, 5, and
7 days post-injury. We show that inhibition of Egr2-AS-RNA
expression results in significant preservation of PMP22 and
MPZ protein expression 7 days following complete sciatic nerve
transection (Figures 4B and 4C). The delayed inhibition of struc-
tural myelin proteins correlates with the delay in demyelination
observed after inhibition of Egr2-AS-RNA expression (Figures
3C–3E).
Egr2-AS-RNA Inhibits Nascent Transcription ofEgr2 and
Mediates Gradual Recruitment of a Chromatin
Remodeling Complex on the Egr2 Promoter
In order to distinguish whether the effect of Egr2-AS-RNA on
Egr2 expression is due to a direct effect on transcription, we
performed nuclear run-on assays in SCs infected with Lenti-
AS-RNA or Lenti-control. We show that expression of Egr2-
AS-RNA results in statistically significant inhibition of nascent
transcription of Egr2 (Figure 5A).
To determine whether Egr2-AS-RNA participates in the for-
mation of a chromatin remodeling complex on the Egr2 pro-
moter, we performed chromatin immunoprecipitation (ChIP)
using sciatic nerve chromatin with antibodies against EZH2,
AGO1, AGO2, or tri-methylated histone 3 (H3K27Me3) followed
by qPCR to detect the presence of the Egr2 promoter and
Egr2-AS-RNA in the complex. This revealed that 48 hr after
sciatic nerve injury, EZH2, AGO1, AGO2, and H3K27me3 are
localized on the Egr2 promoter, and this interaction is inhibited
after treatment with RNase H, which means that the interaction
requires the presence of an RNA-DNA hybrid (Figure 5B). Next,
we asked whether Egr2-AS-RNA is the RNA species respon-
sible for the recruitment of the remodeling complex on the(E) Quantification of the total number of myelinated axons in 15 random sem
nerve transection. Animals treated with hydrogel plus AS-RNA GapMers have a s
sciatic nerve transection than untreated animals or animals treated with hydrog
samples).Egr2 promoter following sciatic nerve injury. We performed
ChIP using chromatin from injured sciatic nerves 6, 24, and
48 hr after injury. To identify the effect of the Egr2-AS-RNA
on the recruitment of EZH2, AGO1, AGO2, and H3K27me3 on
the Egr2 promoter, we inhibited the expression of Egr2-AS-
RNA with the addition of hydrogel plus GapMer, while control
nerves were treated with hydrogel plus scrambled GapMer.
We show that 6 hr post-injury, only AGO1 and AGO2 are pre-
sent on the Egr2 promoter, and inhibition of Egr2-AS-RNA
expression inhibits their recruitment on the promoter (Fig-
ure 5C). At 24 hr post-injury, AGO2 and H3K27me3 are present,
and inhibition of Egr2-AS-RNA expression abolishes their
recruitment on the Egr2 promoter (Figure 5D). At 48 hr post-
injury EZH2, AGO1, AGO2, and H3K27me3 are all recruited
to the Egr2 promoter, and this depends on the presence of
the Egr2-AS-RNA, since inhibition of its expression results in in-
hibition of EZH2, AGO1, AGO2, and H3K27me3 binding to the
Egr2 promoter (Figure 5E). To discover whether the gradual
recruitment of the repressive complex by Egr2-AS-RNA medi-
ates transcriptional repression of Egr2 mRNA, we compared
the ChIP results with the expression of Egr2 mRNA at 6, 24,
and 48 hr following sciatic nerve injury. We show that 6 hr
post-injury, where Egr2-AS-RNA recruits AGO1 and AGO2 on
the Egr2 promoter (Figure 5C), Egr2 transcription is repressed
and inhibition of Egr2-AS-RNA with specific GapMers induces
a significant (38-fold) increase in Egr2 expression compared
to injured nerves treated with scrambled GapMers (Figure 5F,
6 hr). At 24 hr post-injury, the Egr2-AS-RNA mediated recruit-
ment of AGO2 and H3K27me3 to the Egr2 promoter (Figure 5D)
does not correlate with Egr2 transcriptional repression, since
levels of the Egr2 transcript are equal between injured nerves
treated with AS-RNA GapMers and those treated with scram-
bled GapMers (Figure 5F, 24 hr). Finally, at 48 hr post-
injury, the Egr2-AS-RNA-mediated recruitment of EZH2,
AGO1, AGO2, and H3K27me3 to the Egr2 promoter (Figure 5E)
correlates with a modest but significant transcriptional repres-
sion of Egr2, since inhibition of Egr2-AS-RNA expression with
GapMers induces a 3-fold increase in Egr2 transcript levels
compared to injured nerves treated with scrambled GapMers
(Figure 5F, 48 hr).
Expression of Egr2-AS-RNA Is Regulated by ERK1/2
Signaling
Since Egr2-AS-RNA has a direct effect on the expression of Egr2
transcript and protein levels (Figures 1, 2, 3, 4, and S1), we hy-
pothesized that neuregulin-mediated ERK1/2 signaling could
affect the expression of Egr2-AS-RNA in SCs, since it has also
been shown to affect the expression levels of Egr2 (Newbern
et al., 2011). Inhibition of neuregulin-induced ERK1/2 activation
using UO126 in SCs results in significant inhibition of ERK1/2
phosphorylation, significant reduction of EGR2 protein levels
(Figures 6A and 6B), significant upregulation of Egr2-AS-
RNA expression, and inhibition of Egr2 transcript expressionithin sections from an area extending 0.5 mm to 5 mm distal to the sciatic
ignificantly higher number of myelinated fibers 2 and 5 days following complete
el plus scrambled GapMers (*p < 0.05, two-tailed Student’s t test of unpaired
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Figure 4. The Egr2-AS-RNA Regulates Egr2 Gene and Egr2 Target Gene Expression during the Nerve Injury Response
(A) Volcano plots of log2 fold change (FC) for EGR2-regulated genes in non-injured versus injured sciatic nerves and injured nerves versus injured nerves treated
with hydrogel plus GapMers. The x axis shows the log2 of the FC between the conditions. The vertical central line represents no difference in expression, and the
area between the two equidistant lines on both sides of the central line includes genes showing a non-significant change of expression (black dots). On the left
side of the lines, the genes with a negative FC are depicted (decreased expression, blue dots), while on the right side of the lines, the genes with a positive FC
(increased expression) are shown (yellow dots). The y axis shows the log of the p value, which means that genes with low p value (more significant) appear
toward the top of the plot. The horizontal line divides the significant results (p < 0.005, above) from the non-significant (below).
(B) Representative results from three independent experiments using two sciatic nerve isolates 2, 5, and 7 days post-injury showing expression of PMP22 and
MPZ. Actin was used as a loading control.
(legend continued on next page)
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(Figure 6C). Our data suggest that neuregulin-mediated ERK1/2
signaling is a negative regulator of Egr2-AS-RNA expression in
SCs. Recently, it was shown that loss of axonal contact causes
SCs to induce NRG1 type I expression through a mitogen-acti-
vated protein kinase (MAPK)-dependent pathway (Stassart
et al., 2013). We sought to determine whether NRG1 type III or
type I has a distinct role in the expression of Egr2-AS-RNA. We
found that stimulation of SCswith NRG1 type III is themain signal
that exerts an acute negative regulation of the expression of
Egr2-AS-RNA (Figure S4). NRG1 type I did not have any effect
after 3 hr but caused a gradual inhibition of Egr2-AS-RNA
expression at 6 hr and 24 hr. Our data could explain the
acute increase in the expression of Egr2-AS-RNA immediately
after nerve injury (Figure 1C), while the gradual inhibition of
Egr2-AS-RNA expression 24 hr post-injury (Figure 1C) may
reflect gradual inhibition by NRG1 type I as SCs induce its
expression.
NRG1-Induced ERK1/2 Signaling Leads to YY1-
Mediated Regulation of Egr2-AS-RNA
Recently, it was shown that the transcription factor YY1 is part
of the ERK1/2 signaling pathway responsible for the upregula-
tion of EGR2 in response to NRG1 in SCs (He et al., 2010). We
examined whether the increase in Egr2-AS-RNA expression af-
ter inhibition of ERK1/2 signaling (Figure 6C) depends on YY1
modulation of Egr2-AS-RNA. We identified a 100-nt-long region
of the Egr2 promoter upstream of the transcription start site
(TSS) flanking the 50 end of Egr2-AS-RNA (Figure 6D) that con-
tains a previously described YY1-binding motif on the antisense
strand (He et al., 2010) and could possibly regulate the expres-
sion of Egr2-AS-RNA (S1 region; Figure S5A). To determine
whether YY1 directly associates with this region in living cells,
we performed ChIP. We then tested the recruitment of YY1 to
the S1 region of the Egr2 promoter and to a separate region
(S2) located further upstream of the Egr2 promoter (between nu-
cleotides 723 and 647, related to the TSS of Egr2) that con-
tains a conserved YY1-binding motif. YY1 was recruited to the
S2 region of the Egr2 promoter only in SCs incubated in the
presence of NRG1, which agrees with a previous study showing
that YY1 binds to the Egr2 promoter (He et al., 2010). Inhibition
of ERK1/2 signaling with UO126 results in partial but significant
inhibition of YY1’s interaction with the Egr2 promoter (Figure 6E).
Next, we examined whether YY1 associates with the S1 and S2
regions of single-stranded RNA using RNA immunoprecipitation
(RIP). Inhibition of ERK1/2 signaling with UO126 results in a
significantly increased association of YY1 with the S1 and S2 re-
gions of Egr2-AS-RNA (Figure 6F). Our data indicate that NRG1-
ERK1/2 signaling increases YY1 binding to the Egr2 promoter
and activates Egr2 transcription while repressing the expression
of Egr2-AS-RNA. Inhibition of ERK1/2 signaling results in de-
repression of Egr2-AS-RNA expression (Figure 6C) through
increased binding of YY1 to the S1 and S2 regions of(C) Densitometric analysis of the western blot results showing that 7 days after
animals treated with hydrogel plus AS-RNA GapMers than in injured animals or in
normalized to the expression of actin and presented asmean ± SD from three inde
0.001, F (3, 4) = 25.87 for PMP22, p = 0.0019, F (2,6) = 21.3 for MPZ) followed bEgr2-AS-RNA (Figure 6F) and inhibition of Egr2 expression
(Figure 6C).
YY1 Regulates Binding of Egr2-AS-RNA to EZH2
Since inhibition of ERK1/2 signaling in SCs increases binding of
YY1 to Egr2-AS-RNA (Figure 6F), we tested whether YY1 affects
the functional interactions of Egr2-AS-RNA with chromatin re-
modeling complexes. It was previously determined that EED
and EZH2 are core components of a multi-subunit histone meth-
yltransferase complex, PRC2, with specificity for lysine 27
(H3K27) of histone H3 (Cao et al., 2002; Czermin et al., 2002;
M€uller et al., 2002). We hypothesized that Egr2-AS-RNA inter-
acts physically with protein components of the PRC2 and that
YY1 mediates this interaction. We silenced total YY1 expression
in SCs using small interfering RNAs (siRNAs) targeting four sepa-
rate areas of the YY1 sequence (Figure 6G). Then, we performed
RIP with ChIP-validated antibodies against EZH2, AGO1, AGO2,
and H3K27me3 using RNA from YY1 siRNA or non-targeting
siRNA-transfected SCs. In control SCs (non-targeting siRNA
transfected), the Egr2-AS-RNA binds and precipitates exclu-
sively with EZH2 (Figure 6H). Following YY1 knockdown in
YY1-siRNA-transfected SCs, we detected complete loss of
binding of Egr2-AS-RNA to EZH2 and increased binding of
Egr2-AS-RNA to AGO1 (Figure 6H). This may affect turnover
of Egr2-AS-RNA, since AGO proteins have been previously
implicated in ncRNA turnover (Yoon et al., 2015), or it may
indicate a ‘‘switch’’ in Egr2-AS-RNA’s function from RPC2-
mediated chromatin remodeling to AGO-mediated transcrip-
tional silencing (Janowski et al., 2006). Finally, we show that
inhibition of YY1 inhibits Egr2 mRNA expression and induces
Egr2-AS-RNA expression (Figure S5B).
The Phosphorylation State of YY1 Regulates Binding to
Egr2-AS-RNA
Recently, it was shown that NRG1-mediated MEK-ERK1/2
signaling induces phosphorylation of YY1 at serine 118
(Ser118), Ser184, and Ser247, and this phosphorylation has a
key role in regulating Egr2 transcription (He et al., 2010). We
hypothesized that the binding of YY1 to Egr2-AS-RNA may
be regulated by the state of phosphorylation of YY1 serine res-
idues. We generated several Ser-Ala mutations at positions
118, 184, and 247 and a double mutation at positions 118
and 184. To determine the effect of the loss of each serine
on the binding of YY1 to Egr2-AS-RNA, we performed RIP fol-
lowed by qPCR detection of Egr2-AS-RNA. We show that loss
of Ser118 results in significant inhibition of the binding of YY1 to
Egr2-AS-RNA as compared to non-mutated YY1. However,
loss of Ser184 induces a significant increase in binding of
YY1 to Egr2-AS-RNA, while Ser247 has no effect compared
to the non-mutated construct (Figure 6I). Finally, the double
mutation of Ser118 and Ser184 results in increased binding
of YY1 to Egr2-AS-RNA compared to the non-mutated protein,sciatic nerve injury, PMP22 and MPZ exhibit significantly higher expression in
jured animals treated with hydrogel plus scrambled GapMers. The results are
pendent experiments. Significance was calculated with a one-way ANOVA (p <
y a post hoc Dunnett test (**p < 0.005).
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Figure 5. Egr2-AS-RNA Mediates Gradual Recruitment of a Remodeling Complex on the Egr2 Promoter
(A) Expression of Egr2-AS-RNA induces a statistically significant decrease in nascent transcription of Egr2 as quantified by qPCR (n = 8 in control cells, n = 9 in
Egr2-AS-RNA cells, 3 independent experiments, p = 0.0012, t = 3.967, df = 15).
(B) In vivo ChIP using sciatic nerve chromatin with antibodies against EZH2, AGO1, AGO2, and H3K27Me3with or without RNase H. Graph shows themean ± SD
from three independent experiments using sciatic nerves from three animals per experiment. Normalization was performed with values acquired from ChIP with
isotype-matched IgG. Significance was calculated with an unpaired two-tailed Student’s t test (p = 0.040, t = 4.836, df = 2 for EZH2; p = 0.044, t = 2.902, df = 4 for
AGO1; p = 0.045, t = 4.514, df = 2 for AGO2; and p = 0.0012, t = 4.348, df = 4 for H3K27).
(C–E) In vivo DNA ChIP using chromatin from injured sciatic nerves 6, 24, and 48 hr after injury. At 6 hr post-injury, only AGO1 and AGO2 are present on Egr2
promoter, and inhibition of Egr2-AS-RNA expression inhibits their recruitment on the promoter (3 independent experiments; unpaired two-tailed Student’s t test,
p = 0.012, t = 5.710, df = 4 for AGO1; and p = 0.023, t = 2.105, df = 4 for AGO2) (C). At 24 hr post-injury, AGO2 andH3K27me3 are present, and inhibition of AS-RNA
expression abolishes their recruitment on the Egr2 promoter (3 independent experiments; unpaired two-tailed Student’s t test, p = 0.029, t = 2.832, df = 6 for
AGO2; and p = 0.049, t = 2.232, df = 10 for H3K27me3) (D). At 48 hr post-injury, EZH2, AGO1, AGO2, and H3K27me3 are all recruited on the Egr2 promoter, and
this depends on the presence of Egr2-AS-RNA, since inhibition of AS-RNA expression results in inhibition of EZH2, AGO1, AGO2, and H3K27me3 binding on the
Egr2 promoter (3 independent experiments; unpaired two-tailed Student’s t test, p = 0.033, t = 3.188, df = 4 for EZH2; p = 0.017, t = 3.921, df = 4 for AGO1; p =
0.018, t = 3.826, df = 4 for AGO2; and p = 0.035, t = 2.714, df = 6 for H3K27me3) (E).
(F) Transcript expression of Egr2 6 hr, 24 hr, and 48 hr post-injury using RNA from injured sciatic nerves treated with AS-RNA GapMers or scrambled GapMers.
The results are presented as fold change of Egr2 transcript expression in AS-RNA-GapMer-treated nerves versus scrambled-GapMer-treated nerves. The
experiment was repeated three times, and the data are presented as mean ± SD. Fold change above 2 was set arbitrarily and is used in conjunction with p < 0.05
to determine significant differences in gene expression.suggesting that Ser184 is the dominant regulatory site
(Figure 6I).
DISCUSSION
Studies on genetically modified mice (Decker et al., 2006; Le
et al., 2005; Topilko et al., 1994) and identification of the muta-
tions associated with peripheral neuropathies (Bellone et al.,
1999; Timmerman et al., 1999; Warner et al., 1998) have impli-1958 Cell Reports 20, 1950–1963, August 22, 2017cated EGR2 as a central regulator of peripheral myelination (Sva-
ren and Meijer, 2008). During myelination, various SC genes are
dynamically regulated, and the majority of these genes are tar-
gets of EGR2 transcriptional control (D’Antonio et al., 2006;
Jang et al., 2010; Nagarajan et al., 2001; Verheijen et al., 2003).
Recently, the transcription factor YY1 has been implicated as a
molecular link between extracellular signals and the regulation
of EGR2 expression (He et al., 2010). Although the importance
of trans-acting proteins (e.g., transcription factors) has been
Figure 6. Role of NRG1-ERK1/2 Signaling and YY1 in the Regulation of Egr2-AS-RNA Expression
(A) Inhibition of NRG1-induced Erk1/2 phosphorylation in SCs using UO126 results in inhibition of phopsho-ERK1/2 expression and loss of EGR2 expression.
Total ERK1/2 and actin were used as loading controls.
(B) Densitometric quantification of inhibition of ERK1/2 phosphorylation and EGR2 expression following incubation of SCs with UO126. Results are presented as
mean ±SD from three independent experiments using two separate protein isolations per experiment per condition (p < 0.0001, t = 8.99, df = 14 for p-ERK1/2 and
p = 0.0054, t = 4.24, df = 6 for EGR2).
(C) qPCR for Egr2-AS-RNA and Egr2 mRNA following inhibition of ERK1/2 signaling with UO126 in SCs shows significant increase of Egr2-AS-RNA levels and
inhibition of Egr2 mRNA expression (n = 3 independent experiments; unpaired two-tailed Student’s t test; p = 0.044, t = 2.44, df = 7 for Egr2-AS-RNA and p =
0.017, t = 4.32, df = 5 for Egr2).
(D) Schematic showing the position of the S1 site upstream of the Egr2 transcription start site (TSS) and flanking the 50 end of AS-RNA. This site (100 nt) contains
a YY1-binding motif and a TATA box (red sequence) in both sense and antisense orientations. MSE stands for myelin-specific element, which is located at the 30
UTR of the Egr2 gene.
(legend continued on next page)
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established, the existence of an epigenetic circuit that allows
SCs to regulate the expression of EGR2 in response to injury
and during myelination has not been previously described. The
discovery that the majority of eukaryotic genomes are tran-
scribed (ENCODE Project Consortium et al., 2007) and that
many of the resulting transcripts are developmentally regulated
(Mercer et al., 2008) but do not encode proteins (Simon et al.,
2011) has steered our attention toward the role of lncRNA in
the regulation of Egr2 transcription.
We discovered a cis-acting lncRNA antisense to the promoter
of Egr2. Since ectopic expression of Egr2-AS-RNA inhibits the
expression of Egr2mRNA, we asked whether Egr2-AS-RNA ex-
erts reversible regulation of Egr2 expression during peripheral
nerve injury. During the acute phase of the nerve injury response,
the expression of EGR2 is inhibited, and demyelination ensues
(Guertin et al., 2005; Parkinson et al., 2008). We determined
that Egr2-AS-RNAmediates the inhibition of Egr2mRNA expres-
sion, while inhibition of Egr2-AS-RNA expression results in de-
layed demyelination, even after complete nerve transection. In
addition, inhibition of Egr2-AS-RNA expression restores Egr2
transcript expression levels and rescues the EGR2-regulated
gene expression profile in injured nerves. These data raised a se-
ries of questions regarding how the expression of Egr2-AS-RNA
is regulated and how Egr2-AS-RNA is integrated within the path-
ways that control the nerve injury response. It has been shown
that c-Jun is an essential transcription factor for the reprogram-
ming of mature myelinating SCs to de-differentiated SCs after
nerve injury (Arthur-Farraj et al., 2012). c-Jun inhibits Egr2-medi-
ated myelin gene expression (Parkinson et al., 2008) and is a
negative regulator of myelination, which suggests a possible
interplay between Egr2-AS-RNA expression and c-Jun during
the acute nerve injury response.
The expression of EGR2 depends on NRG1-mediated ERK1/2
signaling to YY1 during peripheral myelination (He et al., 2010;
Newbern et al., 2011). We identified a portion of the Egr2 pro-
moter adjacent to the TSS that fulfills the criteria for a bidirec-
tional promoter containing a TATA box and a YY1-binding motif(E) YY1 DNA-ChIP using chromatin isolated from SCs that were untreated or treat
the S1 and S2 regions of the Egr2 promoter was examinedwith qPCR. YY1 associa
inhibited after treatment with UO126. The experiments were repeated three times
Student’s t test (p = 0.0012, t = 28.96, df = 12).
(F) RNA immunoprecipitation (RIP) using RNA isolated from SCs that were untreate
YY1 with the S1 and S2 regions of AS-RNA was examined with qPCR. The expe
Significance was calculated with a Student’s t test (p = 0.0085, t = 3.842, df = 6
(G) SCs transfected with YY1 siRNA for 48 hr show inhibition of YY1 protein expr
used as a loading control.
(H) RIP with antibodies against EZH2, AGO1, AGO2, and H3K27me3 using RNA fr
as mean ± SD from three independent experiments (unpaired two-tailed Student
AGO1).
(I) RIP using DDK antibody (OriGene) followed by qPCR detection of Egr2-AS-RN
non-mutated YY1-DDK. However, loss of Ser184 induced a significant increase in
the non-mutated construct. The double mutation of Ser118 and Ser184 results
protein. The experiment was repeated three times, and results are presented as
Dunnett test [*p = 0.0281]).
(J) Schematic representation of the AS-RNA-mediated regulation of Egr2 expre
which in turn activates the transcription of Egr2 and represses the expression of th
possible conjunction with protein phosphatases blocks Ser184 phosphorylation o
non-phosphorylated YY1 with AS-RNA and activation of AS-RNA expression. Lo
results in inhibition of Egr2 transcription (right).
1960 Cell Reports 20, 1950–1963, August 22, 2017(Smale and Kadonaga, 2003). Although this bidirectional pro-
moter affects expression of Egr2-AS-RNA, we cannot target it
to generate mice lacking expression of Egr2-AS-RNA, since
this approach will also affect expression of Egr2 mRNA through
elimination of the TATA box and several transcription factor (TF)-
binding sites (Rangnekar et al., 1990). YY1 has been previously
implicated in the transcriptional activation of Xist during the
initiation and maintenance of X inactivation through direct
activation of the Xist promoter (Makhlouf et al., 2014). It has
also been shown that YY1 is an RNA-binding protein that binds
Xist as an adaptor protein between the lncRNA and chromatin
targets (Jeon and Lee, 2011). Here, we discovered that YY1 me-
diates the binding of Egr2-AS-RNA to EZH2, which is the core
component of the PRC2 chromatin remodeling complex. How
this function of YY1 is regulated and the biologic significance
of this function during the nerve injury response is unknown. It
is possible that YY1 functions as a molecular scaffold that coor-
dinates targeting of Egr2-AS-RNA to PRC2 and chromatin,
thereby coupling expression of Egr2-AS-RNA with transcrip-
tional repression.
The various functions of YY1 can be modulated by post-trans-
lational modifications, including phosphorylation (Rizkallah and
Hurt, 2009). We describe here a YY1 phospho-switch mecha-
nism (Figure 6J) that regulates binding of YY1 to Egr2 mRNA or
Erg2-AS-RNA. We identified Ser184 as the regulatory site that
induces binding of YY1 to Egr2-AS-RNA. It has been shown
that Aurora B kinase phosphorylates Ser184 of YY1 during
G2/M transition of the cell cycle and that protein phosphatase
1 (PP1) rapidly dephosphorylates YY1 at Ser184 (Kassardjian
et al., 2012). It is possible that dephosphorylation of YY1
following peripheral nerve injury is cell-cycle dependent as SCs
dedifferentiate and that PP1 plays a role in this process.
The speed at which a cell responds to an extracellular cue by
activating a set of genes and repressing another is of pivotal
importance to the fate of that cell. However, this aspect of
gene regulation is often not appreciated. Instead, the absolute
levels of expression are generally seen as the hallmarks of aed with UO126 in the presence of NRG1 overnight. The association of YY1 with
tes only with the S2 region of the Egr2 promoter, and the association is partially
, and results are presented as mean ± SD. Significance was calculated with a
d or treated with UO126 in the presence of NRG1 overnight. The association of
riments were repeated three times, and results are presented as mean ± SD.
for S2 and p = 0.0362, t = 3.099, df = 4 for S1).
ession as compared to SCs transfected with non-targeting siRNAs. Actin was
om YY1 siRNA or non-targeting siRNA transfected SCs. Results are presented
’s t test; p = 0.04, t = 2.445, df = 8 for EZH2 and p = 0.014, t = 3.095, df = 8 for
A. Loss of Ser118 inhibits the binding of YY1 to Egr2-AS-RNA as compared to
the binding of YY1 to Egr2-AS-RNA, while Ser247 has no effect compared to
in increased binding of YY1 to Egr2-AS-RNA compared to the non-mutated
mean ± SD (one-way ANOVA [(5,12) = 3.398, p = 0.0383] followed by post hoc
ssion. In non-injured nerves, NRG1 signaling to ERK1/2 phosphorylates YY1,
e AS-RNA (left). Nerve injury inhibits the NRG1-ERK1/2 signaling axis, which in
f YY1. This results in activation of the YY1 phospho-switch and association of
ss of YY1 phosphorylation and an increase in the expression of the AS-RNA
regulated gene (Uhler et al., 2007). Here, we have shown that
an antisense RNA transcript that associates with Egr2 promoter
in cis regulates the levels of Egr2 transcription in response to
extracellular signals. We propose that Egr2-AS-RNA confers
transcriptional buffering to maintain the proper levels of Egr2
transcription. Given that non-coding AS-RNAs are often ex-
pressed in a tissue- or time-dependent manner, the mechanism
of Egr2-AS-RNA regulation of Egr2 transcription involves chro-
matin remodeling and affects the rate of Egr2 induction rather
than the steady-state levels of gene expression. In fact, we
have shown that Egr2-AS-RNA gradually recruits a chromatin
remodeling complex on the Egr2 promoter, and its role in
chromatin plasticity and transcriptional silencing of Egr2 is
instructive, since inhibition of Egr2-AS-RNA results in the disso-
ciation of the remodeling complex from the Egr2 promoter.
We have identified an antisense RNA that is induced after
nerve injury and regulates the transcription of Egr2 as part of
an NRG1-ERK1/2-YY1 signaling axis. This functional exploration
of an antisense lncRNA in SC biology will likely have a major
impact on our understanding of the transcriptional regulation of
peripheral myelination.
EXPERIMENTAL PROCEDURES
50-RACE
For 50-RACE, we used the RLM RACE kit from Ambion, with certain modifica-
tions. Total RNA was treated with calf intestine alkaline phosphatase (CIP) to
remove free 50 phosphates from molecules such as ribosomal RNA, frag-
mented mRNA, tRNA, and contaminating genomic DNA. The cap structure
found on intact 50 ends of mRNA is not affected by CIP. The RNA was then
treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure
from full-length mRNA, leaving a 50 monophosphate. A 45-base RNA adaptor
oligonucleotide provided by Ambion was ligated to the RNA population using
T4 RNA ligase. The adaptor cannot ligate to dephosphorylated RNA, because
these molecules lack the 50 phosphate necessary for ligation. During the liga-
tion reaction, the majority of the full-length, decapped mRNA acquires the
adaptor sequence as its 50 end. We then used random sense decamers that
bind to the antisense strand and a primer antisense to the 50 adaptor in order
to amplify the AS-RNA.
Computational Verification of the Egr2-AS-RNA Expression
RNA-seq raw reads from mouse sciatic nerves in samples SRR3222412,
SRR3222413, and SRR3222414 were downloaded from the GEO data-
sets (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2086001).
Reads were aligned to the mm10 assembly of the mouse genome with
gsnap (Wu and Nacu, 2010). Read mapping to genes was done based on
the RefSeq exons, as defined in file http://hgdownload.cse.ucsc.edu/
goldenPath/mm10/database/refGene.txt.gz. The coordinates of the AS-
RNA on chr10 were added to the exon file. Read summarization was done
with featureCounts (Liao et al., 2014), and raw read counts were standard-
ized to the RPKM measure (Mortazavi et al., 2008) using reads with a map-
ping quality of 20 or better. To estimate the coordinates of the mature RNA,
we first looked at the sequenced reads around the appropriate genomic
location using the mpileup routine of SAMtools (Li et al., 2009), and then
we visualized the reads using the Integrative Genomics Viewer (Robinson
et al., 2011) as confirmation.
Chromatin Isolation from Sciatic Nerves
2-month-old mice were subjected to sciatic nerve transection. 48 hr after
injury, the animals were euthanized, and both nerves (distal part of the lesioned
nerve and a 0.5 mm fraction of the contralateral healthy nerve) were isolated.
Nerves (5 per condition) were then crosslinked with 1% paraformaldehyde
(PFA) in PBS and neutralized with glycine (0.3 M final concentration). Nerveswere centrifuged at 2,000 relative centrifugal force (rcf) for 5 min and washed
twice with cold PBS plus protease and nuclease inhibitors. Immunoprecipita-
tion lysis buffer was added to the nerves (EpiTecht ChIP OneDay Kit; QIAGEN,
Venlo, Netherlands), and the nerves were homogenized mechanically for 15 s
with a Pro 200 homogenizer (Proscientific Inc.). Next, the samples were soni-
cated on ice using the Misonix Sonicator 3000 (Fisher Scientific) for 9 cycles of
30 s on and 90 s off at 80% power to shear the chromatin between 100 and
1,000 bp. For ChIPs using SCs, we used components of the EpiTecht ChIP
OneDay Kit. Chromatin was sonicated to an average length of 1–2 kb on ice
and centrifuged. The supernatant was used for RNA or DNA ChIP.
DNA ChIP
Lysates were incubated overnight at 4C on rotation with the ChIP-verified
antibodies Ezh2, Ago1, and Ago2 (Cell Signaling, Danvers, MA, USA) at a
1:50 dilution or H3K27 (Millipore, Billerica, MA, USA) at a dilution of 1:25 or
without antibody as a control. Chromatin was then precipitated, and DNA
was extracted (EpiTecht ChIP OneDay Kit). Recovered material from the input
sample and all the ChIP samples per condition were used to perform qPCR
of the Egr2 AS-RNA (for primer sequences, see Supplemental Experimental
Procedures). Relative enrichment for each experimental sample was calcu-
lated as a percentage of the input. For negative control ChIP, we used a
non-targeting isotype-matched immunoglobulin G (IgG), and the values in all
experiments ranged between 0% and 0.002% of the input sample. These
values were used to normalize the data obtained with the target-specific
antibodies. For all qPCRs reported in the paper, we performed a no-reverse
transcription (RT) control amplification to verify the absence of genomic
DNA contamination.
RIP
To perform RIP, we used the magnetic ChIP kit (RNA ChIP-IT; Active Motif,
Carlsbad, CA, USA). The antibodies used, analysis, and plotting were the
same as those described for DNA ChIP.
Statistical Analysis
To determine statistical significance among the means of three or more inde-
pendent groups, we used one-way ANOVA. The homogeneity of variances
was confirmed with Brown and Forsythe test, and the significance between
specific groups was calculated with a post hoc Dunnett test. This analysis
was performed for the data in figures Figures 1C, 1D, 3A, 3B, 4C, and 6I.
For the rest of the data, we used an unpaired two-tailed t test. To verify
Gaussian distribution of the data before applying the t test, we performed
the D’Agostino and Pearson and Shapiro-Wilk normality tests. Statistical anal-
ysis was performed using GraphPad Prism.
Animal Use and Care
8-week-old male and female C57/B6 WT mice (gender does not affect periph-
eral nerve injury response) were obtained from The Jackson Laboratory and
maintained according to the NIHGuide for the Care and Use of Laboratory An-
imals. All animal use protocols were approved by the Institutional Animal Care
and Use Committee of the Weis Center for Research, Geisinger Clinic.
Western Blots
The full scans of all western blots presented in the paper are included in
Figure S6.
Methods for sciatic nerve injury, lentivirus production, mouse DRG explant
and purified SC cultures, immunocytochemistry protocols, RT-PCR and
qPCR, western blotting, preparation of the hydrogel, in situ hybridization
(ISH), nuclear run-on assay, PCR array, electron microscopy, siRNA transfec-
tions, and mutagenesis are included in detail in Supplemental Experimental
Procedures.
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